Bifidobacterium pseudominutus and application thereof in metabolic syndrome

A technology of metabolic syndrome and bifidobacteria, applied to Bifidobacterium pseudominis and its application in metabolic syndrome

Active Publication Date: 2021-07-06
BEIJING QUANTIHEALTH TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, statins are considered to be the most effective lipid-lowering drugs, but there are still some obvious side effects and restrictions on their use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bifidobacterium pseudominutus and application thereof in metabolic syndrome
  • Bifidobacterium pseudominutus and application thereof in metabolic syndrome
  • Bifidobacterium pseudominutus and application thereof in metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Isolation and identification of pseudosmall chain bifidobacteria BPW0

[0036] The separation process of pseudosmall chain bifidobacterium BPW0 provided by the invention is as follows:

[0037] 1. Collection of samples

[0038] The feces of centenarians in Hainan were collected as separate samples. Before the collection, the crowd had never taken antibiotics, had no history of taking probiotics, and had no history of gastrointestinal diseases.

[0039] 2. Isolation of strains

[0040] Dilute the collected feces samples and spread them on YCFA medium, culture anaerobically at 37°C for 24-48 hours, pick a single colony and streak culture on a new YCFA medium plate to obtain purified colonies, and then spread the single colonies On the mass spectrometer plate, the lysate and the matrix were added and dried on the MALDI-TOF MS 1000 mass spectrometer (Autobio, Zhengzhou Antu Biotechnology Co., Ltd.) for identification on the machine. The identification results are ...

Embodiment 2

[0042] Example 2 Preparation of Pseudosmall Chain Bifidobacterium BPW0 Live Bacteria Liquid, Metabolites and Inactivated Bacteria

[0043] 1. Culture of bacteria

[0044] Take -80°C frozen bacteria liquid and spread it on the YCFA solid plate, and after inverting culture at 37°C for 24-48 hours, take a single colony and inoculate it in the liquid YCFA medium, and cultivate it at 37°C for 18-24 hours to obtain the first-generation bacterial liquid; Take 10% of the first-generation bacterial solution and inoculate it into fresh YCFA liquid medium, incubate at 37°C for 18-24 hours to obtain the second-generation bacterial solution; take 10% of the second-generation bacterial solution and inoculate it into fresh YCFA liquid medium, and incubate at 37°C for 18-24 hours to obtain working bacteria.

[0045] 2. Obtaining live bacteria solution

[0046] The live bacterial liquid can also be obtained by other methods in the technical field, as long as the bacterial cells can be enrich...

Embodiment 3

[0052] Example 3 HepG2 cell experiment

[0053] The human-derived liver cancer HepG2 cells used in the present invention are purchased from the National Biomedical Experimental Cell Resource Bank, and the culture method is a conventional culture method used in the field. In one embodiment of the invention, the culture method is: at 37°C and 5% CO 2 Under conditions, culture in high-glucose DMEM medium containing 10% fetal bovine serum (FBS), add double antibodies (100ug / ml penicillin and 100ug / ml streptomycin) in the medium at a ratio of 1:100, every 1-2d Replace with fresh culture medium once.

[0054] The present application acts on the lipid accumulation model constructed by HepG2 cells with the bacterial strain provided by the present invention, and observes the influence of the bacterial strain provided by the present invention on lipid metabolism, specifically as follows:

[0055] 1. Oil red O staining test

[0056] HepG2 cells in logarithmic growth phase in good grow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides Bifidobacterium pseudocatenatum and application thereof in metabolic syndrome, and relates to the field of microorganisms. The preservation number of the Bifidobacterium pseudocatenatum is CGMCC No.22185, the Bifidobacterium pseudocatenatum is preserved in China General Microbiological Culture Collection Center on April 14, 2021, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing. According to the Bifidobacterium pseudocatenatum, the accumulation of liver cell lipid can be significantly inhibited, the body weight and the blood fat level can be reduced, the liver fatty degeneration can be further improved, and the important application significance can be provided for the alleviation of the occurrence of hyperlipidemia, obesity and fatty liver.

Description

technical field [0001] The invention relates to the field of microorganisms, in particular to a pseudo-small chain bifidobacterium and its application in metabolic syndrome. Background technique [0002] Dyslipidemia is an important risk factor for cardiovascular and cerebrovascular diseases. Like many chronic disease risk factors such as hypertension and diabetes, it can lead to coronary heart disease, myocardial infarction, stroke and other cardiovascular and cerebrovascular diseases. Therefore, blood lipid management is currently the focus of prevention and control of cardiovascular and cerebrovascular diseases in our country. With the improvement of people's living standards, changes in diet structure, accelerated pace of life, and increased pressure, the problem of "three highs" has gradually become serious. The prevalence of dyslipidemia alone is as high as 40.4%. According to statistics from the National Center for Cardiovascular Diseases, the number of people with d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N1/20A61K35/745A61P1/16A61P3/06A61P5/00A23L33/135C12R1/01
CPCC12N1/20A61K35/745A61P1/16A61P3/06A61P3/04A23L33/135A23V2002/00A23V2400/535A23V2200/3262A23V2200/332A23V2200/32
Inventor 徐文艺赵柏闻李转羽刘彦宏
Owner BEIJING QUANTIHEALTH TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap